1 / 23

ARVs- Acesso Sustentavel

ARVs- Acesso Sustentavel. Manuel Gon çalves VP , Head Government Affairs ,Communication , Patient Advocacy , Community Partnership , Access Lisboa 18 -03-10. Two Businesses with Complementary Strengths. 3 pipeline assets including a Phase II NNRTI 3 licensed HIV medicines

herve
Download Presentation

ARVs- Acesso Sustentavel

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARVs-AcessoSustentavel Manuel Gonçalves VP , Head Government Affairs ,Communication , Patient Advocacy , Community Partnership , Access Lisboa 18-03-10

  2. Two Businesses with Complementary Strengths • 3 pipeline assets including a Phase II NNRTI • 3 licensed HIV medicines • Highly active IIIb/IV clinical programme for Celsentri • (maraviroc) Pioneered HIV antivirals 7 licensed HIV medicines in 40 countries 4 pipeline products, including 2 IntegraseInhibitors and an NNRTI Prescribing Information is available for all products at this meeting.Registration conditions may differ internationally. Please refer to appropriate country Prescribing Information

  3. Creating Critical Mass – A New approach • Sustainable business • 10 licensed ARV medicines • Stimulate R&D in HIV • 7 pipeline products, including 5 in Phase 2 • 17 molecules to develop as new treatments • MORE PRODUCTS; MORE REACH; MORE FOCUS

  4. ARVs-AcessoSustentavel Manuel Gonçalves VP , Head Government Affairs ,Communication , Patient Advocacy , Community Partnership , Access

  5. HIV/AIDS LMICs– Acesso ARVs • Enorme Progresso : - 2008 : 4 M pessoas tratadas + 36% vs 07 e 10 X 031 M iniciaram Terapeutica em 2008 • MAS : - > 5 M pessoas sem acesso a ARVs

  6. Number of people receiving antiretroviral therapy in low-and middle-income countries, by region, 2002–2008

  7. GAP “Terapeutico” LMICs -2008 • SSA : 3 M em ARVs - 3,7 M sem ARVs • LA : 445 m em ARVs – 370m sem ARVs

  8. OMS – Recomendações TerapeuticasDEC 2009 • Iniciar ARV maiscedo.Antes de ficar “doente” . Iniciarquando CD4 passarbarreira de :350 cells/mm3 • Utilizar regimes terapeuticosmenos toxicos e mais faceis de administrarDiminuirefeitosadversos e aumentar a adesãoterapeutica • Melhorar a terapeutica das co-infecções TB/HIV e HBV/HIV Iniciarterapeuticaem PLHIV com TB e Hepatite B cronicaactivas , independente de niveis de CD4 • UtilizarmelhorosrecursoslaboratoriaisMonitorizarniveis de CD4 e carga viral = Eficiencia e eficáciaterapeuticaaumentadas

  9. Consequências das Novas Recomendações Terapeuticas • + PLHIV a iniciarem Terapeutica • PLHIV vivem mais anos e melhor ! • Aumento dos custos da Terapeutica

  10. CriseEconómica Mundial - Impacto 10-13LDCs • Crescimento do PIB nos LDCs 1-3% • Aumento do desemprego ;redução das remessas dos emigrantes • Financiamento “privado” de ARVs em 2008 +/- 1 B USD • Redução / Estagnação do financiamento externo ( Multilateral, Bilateral, Filantrópico)

  11. GAP Financiamento LMICs 2008 6 mil milhões de USD

  12. Contribuição para Acesso ARVS nos LMICs • Royalty Free Voluntary Licenses e Non For profit prices nos LDCs • Parcerias na Area da terapeutica em Pediatria • Politica de Preços e “Tec –Transfer” nos MICs

  13. Royalty Free Voluntary License Policy nos LDCs • Licenças sem “Royalties” para todos os produtos ViiV Healthcare incluindo pipeline em 64 países • Preços “Non for profit” para todos os produtos ViiV Healthcare em 64 países ; e paratodosos “empregadores” na SSA queprovidenciem ARVs aosseustrabalhadores.

  14. Países Incluídos • Afghanistan, Angola,Bangladesh, Benin,Bhutan, Botswana,Burkina Faso, Burundi, Cambodia, Cameroon,Cape Verde, Central African Republic,Chad, Comoros,Congo, Cote d’Ivoire,Djibouti, DR Congo(Zaire), East Timor, Equatorial Guinea,Eritrea, Ethiopia, Gabon, Ghana,Gambia, Guinea,Guinea Bissau, Haiti,Kenya, Kiribati, LaoPeople’s DR, Lesotho,Liberia, Madagascar,Malawi, Maldives,Mali, Mauritania,Mauritius,Mozambique, Myanmar, Namibia,Nepal, Niger, Nigeria,Rwanda, Samoa, SaoTome and Principe, Senegal, Seychelles,Sierra Leone, SolomonIslands, Somalia, South Africa Sudan,Swaziland, Tanzania,Togo, Tuvalu, Uganda,Vanuatu, Yemen, Zambia, Zimbabwe

  15. Acesso ARVs - MICs • Russia, Mexico, Chile, Venezuela , Brasil, Columbia , India, China, Egypt, Philippines , Malaysia ... • Transferencia de Tecnologia onde possível. (Brasil) • Redução de preços de acordo com GDP / Impacto da pandemia .

  16. Focus em acesso ARVs - Pediatria • Parceria com EGPAF para estudar como melhorar condições de acesso das crianças a ARVs – 3 M USD 7 Países SSA • Parceria com Agencia Mundial para desenvolvimento de FDCs para uso em Pediatria

  17. Positive Action for Children Fund 50 M £ - 10 years • 1. Primary prevention of HIV infection among women of child bearing age; • 2. Preventing unintended pregnancies among women living with HIV; • 3. Preventing HIV transmission from a woman living with HIV to her infant; • 4. Providing appropriate treatment, care and support to mothers living with HIV and their children and families

  18. “The time is always right to do what is right” Martin Luther King

More Related